According to the prescribing information, patients treated with Spravato should receive a dose twice a week for the first ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

total score within 24 hours after the initial dose, with effects sustained for at least four weeks. Spravato’s safety profile aligns with existing data for oral antidepressants, with no new safety ...

In some patients, there was a measurable shift on the MADRS scale within around 24 hours of the first dose, according to J&J. That speed of onset has been held up as the main benefit for Spravato ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

001). Improvements were observed approximately 24 hours after the first dose of Spravato and were sustained through 4 weeks of treatment. “Treatment-resistant depression can be very complicated ...

healthcare providers will now have the option to prescribe Spravato to patients with major depressive disorder, particularly those who haven't responded to previous doses of traditional ...

The double-blinded, randomized, and controlled trial involved people with treatment-resistant depression, who were assigned to three groups: two groups who received different doses of Spravato ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

total score within 24 hours after the initial dose, with effects sustained for at least four weeks. Spravato’s safety profile aligns with existing data for oral antidepressants, with no new ...